Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Moon Bae Ahn 1 Article
Hypothalamus and Pituitary Gland
Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
Yun Jeong Lee, Yunha Choi, Han-Wook Yoo, Young Ah Lee, Choong Ho Shin, Han Saem Choi, Ho-Seong Kim, Jae Hyun Kim, Jung Eun Moon, Cheol Woo Ko, Moon Bae Ahn, Byung-Kyu Suh, Jin-Ho Choi
Endocrinol Metab. 2022;37(2):359-368.   Published online April 25, 2022
DOI: https://doi.org/10.3803/EnM.2021.1384
  • 5,606 View
  • 202 Download
  • 9 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Discontinuing growth hormone (GH) treatment during the transition to adulthood has been associated with adverse health outcomes in patients with childhood-onset growth hormone deficiency (CO-GHD). This study investigated the metabolic changes associated with interrupting GH treatment in adolescents with CO-GHD during the transition period.
Methods
This study included 187 patients with CO-GHD who were confirmed to have adult GHD and were treated at six academic centers in Korea. Data on clinical parameters, including anthropometric measurements, metabolic profiles, and bone mineral density (BMD) at the end of childhood GH treatment, were collected at the time of re-evaluation for GHD and 1 year after treatment resumption.
Results
Most patients (n=182, 97.3%) had organic GHD. The median age at treatment discontinuation and re-evaluation was 15.6 and 18.7 years, respectively. The median duration of treatment interruption was 2.8 years. During treatment discontinuation, body mass index Z-scores and total cholesterol, low-density lipoprotein, and non-high-density lipoprotein (HDL) cholesterol levels increased, whereas fasting glucose levels decreased. One year after GH treatment resumption, fasting glucose levels, HDL cholesterol levels, and femoral neck BMD increased significantly. Longer GH interruption (>2 years, 60.4%) resulted in worse lipid profiles at re-evaluation. The duration of interruption was positively correlated with fasting glucose and non-HDL cholesterol levels after adjusting for covariates.
Conclusion
GH treatment interruption during the transition period resulted in worse metabolic parameters, and a longer interruption period was correlated with poorer outcomes. GH treatment should be resumed early in patients with CO-GHD during the transition period.

Citations

Citations to this article as recorded by  
  • Ghrelin regulating liver activity and its potential effects on liver fibrosis and Echinococcosis
    Jiang Zhu, Tanfang Zhou, Meng Menggen, Kalibixiati Aimulajiang, Hao Wen
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Composición de la microbiota en pacientes con déficit de hormona de crecimiento antes y después de recibir tratamiento
    Patricia García Navas, María Yolanda Ruíz del Prado, Pablo Villoslada Blanco, Emma Recio Fernández, María Ruíz del Campo, Patricia Pérez Matute
    Anales de Pediatría.2024; 100(6): 404.     CrossRef
  • Composition of the microbiota in patients with growth hormone deficiency before and after treatment with growth hormone
    Patricia García Navas, María Yolanda Ruíz del Prado, Pablo Villoslada Blanco, Emma Recio Fernández, María Ruíz del Campo, Patricia Pérez Matute
    Anales de Pediatría (English Edition).2024; 100(6): 404.     CrossRef
  • Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors
    Pedro Iglesias
    Journal of Clinical Medicine.2024; 13(15): 4307.     CrossRef
  • An Overview of Cardiovascular Risk in Pituitary Disorders
    Georgia Ntali, Vyron Markussis, Alexandra Chrisoulidou
    Medicina.2024; 60(8): 1241.     CrossRef
  • The role of IGF1 in determining body composition in children and adolescents with growth hormone deficiency and those with idiopathic short stature
    Hussein Zaitoon, Michal Yackobovitch-Gavan, Eyas Midlej, Adi Uretzky, Irina Laurian, Anna Dorfman, Hagar Interator, Yael Lebenthal, Avivit Brener
    Endocrine.2024;[Epub]     CrossRef
  • Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium
    Willem Staels, Jean De Schepper, Marianne Becker, Philippe Lysy, Daniel Klink, Karl Logghe, Marieken den Brinker, Anne Rochtus, Bruno Lapauw, Martine Cools, Orsalia Alexopoulou, Marie Bex, Bernard Corvilain, Laurent Crenier, Christophe De Block, Julian Do
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Transition Period and Young Adulthood in Patients with Childhood Onset Growth Hormone Deficiency (COGHD): Impact of Growth Hormone Replacement on Bone Mass and Body Composition
    Mirjana Doknic, Marko Stojanovic, Aleksandra Markovic
    International Journal of Molecular Sciences.2024; 25(19): 10313.     CrossRef
  • Baseline Clinical Factors Associated with Cessation of Growth Hormone Therapy in Patients with Severe Growth Hormone Deficiency - Real World Evidence
    Nageswary Nadarajah, Emmanuel Ssemmondo, Shani Brooks, Remi Akinyombo, Kazeem Adeleke, Harshal Deshmukh, Thozhukat Sathyapalan
    International Journal of Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • Relationship between the Stimulated Peak Growth Hormone Level and Metabolic Parameters in Children with Growth Hormone Deficiency
    Seong Yong Lee
    The Ewha Medical Journal.2023;[Epub]     CrossRef
  • Dyslipidaemia and growth hormone deficiency – A comprehensive review
    Matthias Hepprich, Fahim Ebrahimi, Emanuel Christ
    Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(6): 101821.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP